Hierarchical control of coherent gene clusters defines the molecular mechanisms of glioblastoma.

Glioblastoma is a highly-aggressive and rapidly-lethal tumor characterized by resistance to therapy. Although data on multiple genes, proteins, and pathways are available, the key challenge is deciphering this information and identifying central molecular targets. Therapeutically targeting individual molecules is often unsuccessful due to the presence of compensatory and redundant pathways, and crosstalk. A systems biology approach that involves a hierarchical gene group networks analysis can delineate the coherent functions of different disease mediators. Here, we report an integrative networks-based analysis to identify a system of coherent gene modules in primary and secondary glioblastoma. Our study revealed a hierarchical transcriptional control of genes in these modules. We elucidated those modules responsible for conversion of the glioma-associated microglia/macrophages into glioma-supportive, immunosuppressive cells. Further, we identified clusters comprising mediators of angiogenesis, proliferation, and cell death for both primary and secondary glioblastomas. Data obtained for these clusters point to a possible role of transcription regulators that function as the gene modules mediators in glioblastoma pathogenesis. We elucidated a set of possible transcription regulators that can be targeted to affect the selected gene clusters at specific levels for glioblastoma. Our innovative approach to construct informative disease models may hold the key to successful management of complex diseases including glioblastoma and other cancers.

[1]  R. Wheelhouse,et al.  Glioblastoma Multiforme Therapy and Mechanisms of Resistance , 2013, Pharmaceuticals.

[2]  A. Martínez-Torteya,et al.  SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis , 2013, PloS one.

[3]  A. Heimberger,et al.  The Controversial Role of Microglia in Malignant Gliomas , 2013, Clinical & developmental immunology.

[4]  S. Fulda,et al.  Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes , 2013, Cell Death and Differentiation.

[5]  Suzanne F. Jones,et al.  A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. , 2013, European journal of cancer.

[6]  Andrea Califano,et al.  Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. , 2013, Genes & development.

[7]  J. Changeux,et al.  A hierarchical coherent‐gene‐group model for brain development , 2013, Genes, brain, and behavior.

[8]  A. Jaiswal,et al.  The transcription factor NF‐E2‐related Factor 2 (Nrf2): a protooncogene? , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  S. Kimura,et al.  Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells , 2013, Cancer Cell International.

[10]  James U. Bowie,et al.  Network rewiring is an important mechanism of gene essentiality change , 2012, Scientific Reports.

[11]  J. Jordán,et al.  Minocycline Blocks Asthma-associated Inflammation in Part by Interfering with the T Cell Receptor-Nuclear Factor κB-GATA-3-IL-4 Axis without a Prominent Effect on Poly(ADP-ribose) Polymerase* , 2012, The Journal of Biological Chemistry.

[12]  Geng-yin Zhou,et al.  Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. , 2012, Cancer letters.

[13]  A. Brivanlou,et al.  The BMP Inhibitor Coco Reactivates Breast Cancer Cells at Lung Metastatic Sites , 2012, Cell.

[14]  O. Hankinson,et al.  HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation , 2012, Respiratory Research.

[15]  Li Lin,et al.  Abstract 4772: Novel drug discovery approach targeting STAT3 for breast cancer therapy using MLSD and drug repositioning , 2012 .

[16]  G. Pietersz,et al.  Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond , 2012, Nature Reviews Drug Discovery.

[17]  Semi Kim,et al.  ZEB2 upregulates integrin α5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. , 2012, Carcinogenesis.

[18]  X. Jin,et al.  Survival signaling in the preimplantation embryo. , 2012, Theriogenology.

[19]  S. Niture,et al.  Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis* , 2012, The Journal of Biological Chemistry.

[20]  M. Baitaluk,et al.  IntegromeDB: an integrated system and biological search engine , 2012, BMC Genomics.

[21]  P. Crespo,et al.  Mxi2 sustains ERK1/2 phosphorylation in the nucleus by preventing ERK1/2 binding to phosphatases. , 2012, The Biochemical journal.

[22]  Helen Diller Family Targeting the TGFβ signalling pathway in disease , 2012 .

[23]  Daniela Cilloni,et al.  Molecular Pathways: BCR-ABL , 2011, Clinical Cancer Research.

[24]  Y. Zhang,et al.  Effects of DNMT1 silencing on malignant phenotype and methylated gene expression in cervical cancer cells , 2011, Journal of experimental & clinical cancer research : CR.

[25]  Katarzyna M. Wilczynska,et al.  A Complex of Nuclear Factor I-X3 and STAT3 Regulates Astrocyte and Glioma Migration through the Secreted Glycoprotein YKL-40* , 2011, The Journal of Biological Chemistry.

[26]  S. Goodison,et al.  Targeting Sp1 transcription factors in prostate cancer therapy. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[27]  N. Bardeesy,et al.  Cancer: When antioxidants are bad , 2011, Nature.

[28]  J. Leza,et al.  CCL2/MCP-1 modulation of microglial activation and proliferation , 2011, Journal of Neuroinflammation.

[29]  Li Zhang,et al.  ROCK Inhibitor Y-27632 Suppresses Dissociation-Induced Apoptosis of Murine Prostate Stem/Progenitor Cells and Increases Their Cloning Efficiency , 2011, PloS one.

[30]  Stephan Frank,et al.  MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. , 2011, Cancer research.

[31]  Amarnath Gupta,et al.  BiologicalNetworks 2.0 - an integrative view of genome biology data , 2010, BMC Bioinformatics.

[32]  A. Heimberger,et al.  Glioma cancer stem cells induce immunosuppressive macrophages/microglia. , 2010, Neuro-oncology.

[33]  Gongping Xu,et al.  Celecoxib Inhibits β-Catenin-Dependent Survival of the Human Osteosarcoma MG-63 Cell Line , 2010, The Journal of international medical research.

[34]  J Ragoussis,et al.  An oncogenic role of eIF3e/INT6 in human breast cancer , 2010, Oncogene.

[35]  Nader Sanai,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. , 2010, World neurosurgery.

[36]  Y. Marie,et al.  A New Alternative Mechanism in Glioblastoma Vascularization: Tubular Vasculogenic Mimicry , 2022 .

[37]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[38]  P. Keegan,et al.  FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.

[39]  S. Hsu,et al.  1211 Peroxisome proliferator-activated receptor Gamma responsible for TGFβ-induced epithelial mesenchymal transition (EMT) and tumor invasion of NSCLC cells (H460) , 2009 .

[40]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[41]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[42]  L. Chin,et al.  Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.

[43]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[44]  Alejandra Bruna,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[45]  H. Kettenmann,et al.  The invasion promoting effect of microglia on glioblastoma cells is inhibited by cyclosporin A. , 2007, Brain : a journal of neurology.

[46]  Endre Barta,et al.  Comparative genomics-based orthologous promoter analysis using the DoOP database and the DoOPSearch web tool. , 2007, Methods in molecular biology.

[47]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[48]  J. Folkman Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.

[49]  Roberta Diaz Brinton,et al.  Estrogen Receptor Protein Interaction with Phosphatidylinositol 3-Kinase Leads to Activation of Phosphorylated Akt and Extracellular Signal-Regulated Kinase 1/2 in the Same Population of Cortical Neurons: A Unified Mechanism of Estrogen Action , 2006, The Journal of Neuroscience.

[50]  Amarnath Gupta,et al.  BiologicalNetworks: visualization and analysis tool for systems biology , 2006, Nucleic Acids Res..

[51]  M. Klagsbrun,et al.  Neuron Restrictive Silencer Factor NRSF/REST Is a Transcriptional Repressor of Neuropilin-1 and Diminishes the Ability of Semaphorin 3A to Inhibit Keratinocyte Migration* , 2006, Journal of Biological Chemistry.

[52]  V. Jordan,et al.  Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer , 2006, British journal of pharmacology.

[53]  M. Tainsky,et al.  The Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Inhibitor PD184352 (CI-1040) Selectively Induces Apoptosis in Malignant Schwannoma Cell Lines , 2006, Journal of Pharmacology and Experimental Therapeutics.

[54]  M. Weller,et al.  Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. , 2006, Current pharmaceutical design.

[55]  S. Horvath,et al.  Gene connectivity, function, and sequence conservation: predictions from modular yeast co-expression networks , 2006, BMC Genomics.

[56]  A. Sica,et al.  Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1α* , 2005, Journal of Biological Chemistry.

[57]  M. Weiser-Evans,et al.  Patterns of Gene Expression Differentially Regulated by Platelet-derived Growth Factor and Hypertrophic Stimuli in Vascular Smooth Muscle Cells , 2005, Journal of Biological Chemistry.

[58]  R. Kiss,et al.  Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Sung-Hwan Park,et al.  Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor κB-dependent pathway in patients with rheumatoid arthritis , 2004, Arthritis research & therapy.

[60]  Jinshun Zhao,et al.  Molecular Mechanisms of Low Intensity Pulsed Ultrasound in Human Skin Fibroblasts* , 2004, Journal of Biological Chemistry.

[61]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[62]  S. Kasif,et al.  Identification of Transcription Factor Binding Sites Upstream of Human Genes Regulated by the Phosphatidylinositol 3-Kinase and MEK/ERK Signaling Pathways* , 2004, Journal of Biological Chemistry.

[63]  Daniel J Brat,et al.  Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.

[64]  P. Wesseling,et al.  Angiogenesis in brain tumors; pathobiological and clinical aspects , 1997, Journal of Neuro-Oncology.

[65]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[66]  L. Pinna,et al.  One‐thousand‐and‐one substrates of protein kinase CK2? , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[68]  H. Hanafusa,et al.  v-Crk Activates the Phosphoinositide 3-Kinase/AKT Pathway by Utilizing Focal Adhesion Kinase and H-Ras , 2002, Molecular and Cellular Biology.

[69]  A. Jacob,et al.  Convergence of Signaling Pathways on the Activation of ERK in B Cells* , 2002, The Journal of Biological Chemistry.

[70]  A. Gregor,et al.  The prognostic influence of bcl-2 in malignant glioma , 2002, British Journal of Cancer.

[71]  T. Werner,et al.  Regulatory context is a crucial part of gene function. , 2002, Trends in genetics : TIG.

[72]  Allan Balmain,et al.  TGF-β signaling in tumor suppression and cancer progression , 2001, Nature Genetics.

[73]  Michael D. Schneider,et al.  Transforming Growth Factor-β Receptor-associated Protein 1 Is a Smad4 Chaperone* , 2001, The Journal of Biological Chemistry.

[74]  S. E. F. Tran,et al.  MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors* , 2001, The Journal of Biological Chemistry.

[75]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[76]  E. Sahai,et al.  Cross‐talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility , 2001, The EMBO journal.

[77]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[78]  M. Karin,et al.  Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. , 2001, Molecular endocrinology.

[79]  K. Ley,et al.  Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase , 2000, Nature.

[80]  K. Heidenreich,et al.  Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein* , 2000, The Journal of Biological Chemistry.

[81]  J. Dichgans,et al.  BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy , 1999, Journal of neurology, neurosurgery, and psychiatry.

[82]  D. Nemazee,et al.  Distinct Signal Thresholds for the Unique Antigen Receptor–Linked Gene Expression Programs in Mature and Immature B Cells , 1999, The Journal of experimental medicine.

[83]  M. Montminy,et al.  CREB Is a Regulatory Target for the Protein Kinase Akt/PKB* , 1998, The Journal of Biological Chemistry.

[84]  P. Charifson,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. , 1998, Journal of medicinal chemistry.

[85]  Erwin G. Van Meir,et al.  New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-26 , 1997, Oncogene.

[86]  A. Toninello,et al.  Casein kinase 2 phosphorylates recombinant human spermidine/spermine N1-acetyltransferase on both serine and threonine residues. , 1996, Biochemical and biophysical research communications.

[87]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[88]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[89]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .